Tarsus Pharmaceuticals, Inc. TARS Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — operating income (loss) of -$6.12M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss) increased by 76.7% year-over-year, from -$26.28M to -$6.12M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss)?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — operating income (loss) has grown at a 4.2% compound annual growth rate (CAGR), from -$62.71M to -$70.97M.
- What does business segments — operating income (loss) mean?
- Measures the profitability of the business segment by subtracting total operating expenses from total revenues. It indicates the core operational viability and the ability of the segment to generate profit from its primary business activities.